Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02972840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02972840 · ClinicalTrials.gov record · last posted 2026-06-01

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Name: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL — clinical trial record (NCT02972840)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 3

SponsorAcerta Pharma BV

Started2017-04-05

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

Amendment record 45 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 45 times since 2016-11-21; most recent amendment 2026-05-29. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-06-12

Status change Recruiting→Active, Not Recruitingv36

2017-03-28

Status change Not Yet Recruiting→Recruitingv2

Trial Details

NCT Number	NCT02972840
Lead Sponsor	Acerta Pharma BV Collaborators: AstraZeneca
Conditions	Lymphoma, Mantle Cell
Enrollment	635 participants
Start Date	2017-04-05
Primary Completion	2027-02-15 (estimated)
Study Completion	2027-02-15 (estimated)
Updated on ClinicalTrials.gov	2026-06-01